Feedback
Settings

Settings

Goto Application

1. WO2022109106 - EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS

Submit observation
PermaLink
Publication Number WO/2022/109106
Publication Date 27.05.2022
International Application No. PCT/US2021/059847
International Filing Date 18.11.2021
IPC
A61K 31/4433 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non-condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4433containing a six-membered ring with oxygen as a ring hetero atom
A61K 31/4166 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4166having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 45/06 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
CPC
A61K 31/4166
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4166having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
A61K 31/4433
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4433containing a six-membered ring with oxygen as a ring hetero atom
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
Applicants
  • CONSTELLATION PHARMACEUTICALS, INC [US]/[US]
Inventors
  • BRADLEY, William, D.
  • CUI, Jike
  • SUN, Kaiming
  • TROJER, Patrick
  • WANG, Jing
  • WU, Rentian
Agents
  • DAVIS, Steven, G.
  • BENNETT, Coalton, Sundiata
  • ALBURGER, James
  • BAYNE, Christopher, D.
  • BAI, Mei
Priority Data
63/115,16518.11.2020US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS
(FR) THÉRAPIES D'INHIBITION DE L'EZH2 POUR LE TRAITEMENT DE CANCERS DE LA PROSTATE AYANT SUBI UNE MUTATION DU RÉCEPTEUR DES ANDROGÈNES
Abstract
(EN) Provided herein are methods of treating prostate cancer having at least one pathogenic AR mutation using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6- methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5- carboxamide, or a pharmaceutically acceptable salt thereof, alone or in combination with a therapeutically effective amount of an androgen receptor signaling inhibitor (ARSI) such as enzalutamide.
(FR) L'invention concerne des méthodes de traitement d'un cancer de la prostate ayant au moins une mutation du RA pathogène à l'aide de 7-chloro-2-(4-(3-méthoxyazétidin-1-yl)cyclohexyl)-2,4-diméthyl-N-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridin-3-yl)méthyl)benzo[d][1,3]dioxole-5- carboxamide, ou d'un sel pharmaceutiquement acceptable de ce composé, seul ou en combinaison avec une quantité thérapeutiquement efficace d'un inhibiteur de la signalisation du récepteur des androgènes (ARSI), tel que l'enzalutamide.
Latest bibliographic data on file with the International Bureau
# -